Cargando…

PPARα Ligands as Antitumorigenic and Antiangiogenic Agents

Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor family of ligand-activated transcription factors. This subfamily is composed of three members—PPARα, PPARδ, and PPARγ—that differ in their cell and tissue distribution as well as in their target genes. PPARα is abunda...

Descripción completa

Detalles Bibliográficos
Autores principales: Pozzi, Ambra, Capdevila, Jorge H.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2517125/
https://www.ncbi.nlm.nih.gov/pubmed/18725983
http://dx.doi.org/10.1155/2008/906542
_version_ 1782158512809312256
author Pozzi, Ambra
Capdevila, Jorge H.
author_facet Pozzi, Ambra
Capdevila, Jorge H.
author_sort Pozzi, Ambra
collection PubMed
description Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor family of ligand-activated transcription factors. This subfamily is composed of three members—PPARα, PPARδ, and PPARγ—that differ in their cell and tissue distribution as well as in their target genes. PPARα is abundantly expressed in liver, brown adipose tissue, kidney, intestine, heart, and skeletal muscle; and its ligands have been used to treat diseases such as obesity and diabetes. The recent finding that members of the PPAR family, including the PPARα, are expressed by tumor and endothelial cells together with the observation that PPAR ligands regulate cell growth, survival, migration, and invasion, suggested that PPARs also play a role in cancer. In this review, we focus on the contribution of PPARα to tumor and endothelial cell functions and provide compelling evidence that PPARα can be viewed as a new class of ligand activated tumor “suppressor” gene with antiangiogenic and antitumorigenic activities. Given that PPAR ligands are currently used in medicine as hypolipidemic drugs with excellent tolerance and limited toxicity, PPARα activation might offer a novel and potentially low-toxic approach for the treatment of tumor-associated angiogenesis and cancer.
format Text
id pubmed-2517125
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-25171252008-08-21 PPARα Ligands as Antitumorigenic and Antiangiogenic Agents Pozzi, Ambra Capdevila, Jorge H. PPAR Res Review Article Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor family of ligand-activated transcription factors. This subfamily is composed of three members—PPARα, PPARδ, and PPARγ—that differ in their cell and tissue distribution as well as in their target genes. PPARα is abundantly expressed in liver, brown adipose tissue, kidney, intestine, heart, and skeletal muscle; and its ligands have been used to treat diseases such as obesity and diabetes. The recent finding that members of the PPAR family, including the PPARα, are expressed by tumor and endothelial cells together with the observation that PPAR ligands regulate cell growth, survival, migration, and invasion, suggested that PPARs also play a role in cancer. In this review, we focus on the contribution of PPARα to tumor and endothelial cell functions and provide compelling evidence that PPARα can be viewed as a new class of ligand activated tumor “suppressor” gene with antiangiogenic and antitumorigenic activities. Given that PPAR ligands are currently used in medicine as hypolipidemic drugs with excellent tolerance and limited toxicity, PPARα activation might offer a novel and potentially low-toxic approach for the treatment of tumor-associated angiogenesis and cancer. Hindawi Publishing Corporation 2008 2008-08-14 /pmc/articles/PMC2517125/ /pubmed/18725983 http://dx.doi.org/10.1155/2008/906542 Text en Copyright © 2008 A. Pozzi and Jorge H. Capdevila. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Pozzi, Ambra
Capdevila, Jorge H.
PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
title PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
title_full PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
title_fullStr PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
title_full_unstemmed PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
title_short PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
title_sort pparα ligands as antitumorigenic and antiangiogenic agents
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2517125/
https://www.ncbi.nlm.nih.gov/pubmed/18725983
http://dx.doi.org/10.1155/2008/906542
work_keys_str_mv AT pozziambra pparaligandsasantitumorigenicandantiangiogenicagents
AT capdevilajorgeh pparaligandsasantitumorigenicandantiangiogenicagents